News | January 29, 2021
Laurus Q3 FY21 revenue up 76%; PAT grows 274%
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Subscribe To Our Newsletter & Stay Updated
